Vice President of ASH Will Focus on Gene Therapies, ASH's Global Impact
The field of hematology is experiencing significant advancements as promising new therapies for malignancies and GVHD continue to emerge.
Source: onclive.com
Robert Negrin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Negrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Negrin Today - Breaking & Trending Today
Short Interest in Magenta Therapeutics, Inc. (NASDAQ:MGTA) Rises By 21.2%
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 495,600 shares, an increase of 21.2% from the May 15th total of 408,800 shares. Based on an average daily volume of 504,400 shares, the days-to-cover ratio is […]
Source: theenterpriseleader.com
Magenta Therapeutics, Inc. (NASDAQ:MGTA) Short Interest Down 56.0% in May
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 408,800 shares, a drop of 56.0% from the April 30th total of 930,000 shares. Currently, 0.9% of the shares of the company are short sold. Based on […]
Source: wkrb13.com
Inspire Corporate Bond ETF Announces Dividend of $0.07 (NYSEARCA:IBD)
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 408,800 shares, a drop of 56.0% from the April 30th total of 930,000 shares. Based on an average trading volume of 514,400 shares, the […]
Source: dailypolitical.com
Magenta Therapeutics, Inc. (NASDAQ:MGTA) Expected to Post Q2 2023 Earnings of ($0.19) Per Share
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) – Stock analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Magenta Therapeutics in a research report issued on Tuesday, May 16th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their […]
Source: kopsource.com